Use and employer costs of a pharmacotherapy smoking-cessation treatment benefit

被引:9
作者
Burns, Marguerite E.
Rosenberg, Marjorie A.
Fiore, Michael C.
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53726 USA
[2] Univ Wisconsin, Sch Business, Dept Risk Management Actuarial Sci & Insurance, Madison, WI 53706 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Ctr Tobacco Res & Intervent, Dept Med, Madison, WI 53706 USA
关键词
D O I
10.1016/j.amepre.2006.10.003
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Employers cite a lack of information on the cost of insurance coverage for smoking-cessation treatment as a barrier to its provision. This study describes the use of a new insurance benefit for smoking-cessation pharmacotherapy, and its pharmaceutical costs to a large public employer between 2001 and 2003. Methods: Annual enrollment and pharmaceutical claims data were collected from the health plans that contracted with the Wisconsin Department of Employee Trust Funds (ETF). State employees, retirees, and adult dependents who obtained health insurance through the ETF constituted our sample, approximately 150,000/year. Pharmacotherapy benefit use was defined as a paid claim for one of four U.S. Food and Drug Administration-approved smoking-cessation medications. Pharmaceutical cost was defined as the ingredient cost (+) dispensing fee (-) member copayment. Analyses included estimation of the proportion of smokers who used the benefit each year and across 3 years, the average annual cost per user, and the per member per month (PMPM) pharmaceutical cost to the employer. Data were collected from 2001 to 2004 and analyzed in 2005-2006. Results: Annual benefit use among smokers ranged from 6% to 7% with a 3-year rate of approximately 17%. The PMPM cost of the covered pharmacotherapy was approximately $0.13. Conclusions: The cost to employers of providing insurance coverage for smoking-cessation pharmacotherapy to their employees is low. By informing insurance purchasing decisions, these results may facilitate the adoption of much coverage, with the goal of ultimately reducing the proportion of employees who smoke.
引用
收藏
页码:139 / 142
页数:4
相关论文
共 27 条
[1]   Coverage of smoking cessation treatment by union health and welfare funds [J].
Barbeau, EM ;
Li, Y ;
Sorensen, G ;
Conlan, KM ;
Youngstrom, R ;
Emmons, K .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2001, 91 (09) :1412-1415
[2]   How large employers are shaping the health care marketplace - Part 2 [J].
Bodenheimer, T ;
Sullivan, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (15) :1084-1087
[3]   How large employers are shaping the health care marketplace - First of two parts [J].
Bodenheimer, T ;
Sullivan, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (14) :1003-1007
[4]   Employer coverage of clinical preventive services in the United States [J].
Bondi, MA ;
Harris, JR ;
Atkins, D ;
French, ME ;
Umland, B .
AMERICAN JOURNAL OF HEALTH PROMOTION, 2006, 20 (03) :214-222
[5]   Trends - Does insurance coverage for drug therapy affect smoking cessation? [J].
Boyle, RG ;
Solberg, LI ;
Magnan, S ;
Davidson, G ;
Alesci, NL .
HEALTH AFFAIRS, 2002, 21 (06) :162-168
[6]  
Burns Marguerite E, 2005, Prev Chronic Dis, V2, pA15
[7]   Insurance coverage of smoking cessation treatment for state employees [J].
Burns, ME ;
Bosworth, TW ;
Fiore, MC .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2004, 94 (08) :1338-1340
[8]  
Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P54
[9]   Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization [J].
Curry, SJ ;
Grothaus, LC ;
McAfee, T ;
Pabiniak, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (10) :673-679
[10]  
Fiore MC., 2000, TREATING TOBACCO USE